Genomenon Hires New CEO, Prepares to Launch First Product
Ann Arbor, Mich - October 19, 2016 - Genomenon’s Board of Directors recently appointed Mike Klein to the position of Chief Executive Officer as the company prepares to launch its first product, Mastermind, a gene variant knowledge base. Klein is an accomplished CEO with over twenty-five years of experience in developing, building and growing high tech and software companies. He brings technical and financial leadership to the company along with extensive experience in raising capital, acquisitions and delivering successful investor exits.
“I couldn’t be more thrilled to join such an exciting company and founding team” said Klein. “Genomenon’s focus on accelerating clinical diagnostics for cancer patients is an easy mission to get behind, and the technology they’ve licensed from the University of Michigan makes it possible to have a real impact on patient outcomes.”
Genomenon, a software company, spun out of the University of Michigan in 2014 simplifies genetic variant interpretation used for clinical diagnostics in cancer and genetic diseases. The company eliminates the DNA analysis bottleneck with automated tools that deliver fast, comprehensive, up-to-date, evidence-based analysis on DNA variants.
Mastermind, Genomenon’s first product, is a comprehensive knowledge-base built on mining millions of medical publications that automatically finds correlations between genes, variants and diseases tied to the primary scientific literature required for clinical diagnosis of cancer and genetic diseases. Mastermind takes the painstaking process of searching medical literature for disease-causing variants from hours to minutes by automatically sorting through the extensive genomic literature.
Mark Kiel MD, PhD, who has been the driving force behind the company since its founding, will turn over the reigns to Klein to become Chief Scientific Officer and VP of Product Strategy. Kiel’s experience as a clinical pathologist at the University of Michigan lead to the insight and innovation behind Genomenon’s products.
We are very fortunate to have Mike join our team to propel Genomenon forward as we continue to make unprecedented progress toward organizing the world's genomic knowledge to improve the diagnosis and treatment of genetic disease,” said Kiel. “The breadth of his experience and track record of previous successes made him an obvious choice to guide the direction of Genomenon into the next phase of our evolution."
With Klein’s leadership, Genomenon plans to raise additional capital to fund its growth and expand their product offering to improve clinical cancer and genetic diagnosis and treatment.
